Risk/benefit ratio of long-term treatment withβ 2-adrenoceptor agonists

@article{Ziment2007RiskbenefitRO,
  title={Risk/benefit ratio of long-term treatment withβ 2-adrenoceptor agonists},
  author={Irwin Ziment},
  journal={Lung},
  year={2007},
  volume={168},
  pages={168-176}
}
Optimal control of chronic obstructive airway disorders is usually achieved with therapy based onβ 2-adrenoceptor agonist administration. Aerosols are highly effective, have few side effects, allow for fine adjustment of dosage to titrate symptoms, and result in reduction in hyperreactivity. Equivalent bronchodilating doses of oral agents cause side effects… CONTINUE READING